160 related articles for article (PubMed ID: 2914594)
21. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
22. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms accounting for the defective natural killer activity in patients with hairy cell leukemia.
Trentin L; Zambello R; Agostini C; Ambrosetti A; Chisesi T; Raimondi R; Bulian P; Pizzolo G; Semenzato G
Blood; 1990 Apr; 75(7):1525-30. PubMed ID: 2317560
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.
Liberati AM; Horisberger M; Schippa M; Di Clemente F; Fizzotti M; Filippo S; Proietti MG; Arzano S; Berruto P; Palmisano L
Cancer Immunol Immunother; 1991; 34(2):115-22. PubMed ID: 1760815
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 2- and interferon alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia.
Bigda J; Mysliwska J; Baran W; Hellmann A; Mysliwski A
Leuk Lymphoma; 1993 Mar; 9(4-5):371-6. PubMed ID: 8348073
[TBL] [Abstract][Full Text] [Related]
26. Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukemia patients undergoing alpha-interferon therapy.
Wagner L; Goldstone AH; Worman CP
Leukemia; 1989 May; 3(5):373-9. PubMed ID: 2497282
[TBL] [Abstract][Full Text] [Related]
27. Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing.
Gastl G; Aulitzky W; Leiter E; Flener R; Huber C
Blut; 1986 May; 52(5):273-9. PubMed ID: 3635416
[TBL] [Abstract][Full Text] [Related]
28. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
Vokes EE; Bitter MA; Ratain MJ; Prystowsky MB; Daly K; Golomb HM
Cancer; 1987 Jun; 59(12):1987-91. PubMed ID: 3494499
[TBL] [Abstract][Full Text] [Related]
30. Natural killer cell function and malignant cell phenotype in hairy cell leukaemia.
Ogmundsdóttir HM; Thorsteinsson L; Sigfússon A; Sveinsdóttir S; Björnsson S; Eyjólfsson G; Jóhannesson GM; Jensson O
APMIS; 1992 Jan; 100(1):10-20. PubMed ID: 1536717
[TBL] [Abstract][Full Text] [Related]
31. Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application.
Lodemann E; Nitsche EM; Lang MH; Gerein V; Altmeyer P; Holzmann H; Kornhuber B
J Interferon Res; 1985; 5(4):621-8. PubMed ID: 2418131
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
Grups JW; Komprecht B
J Biol Regul Homeost Agents; 1989; 3(3):98-101. PubMed ID: 2516404
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous nuclear RNA from hairy cell leukemia patients activates 2',5'-oligoadenylate synthetase.
Hubbell HR; Sheetz PC; Iogal SS; Brodsky I; Kariko K; Li SW; Suhadolnik RJ; Sobol RW
Anticancer Res; 1991; 11(5):1927-32. PubMed ID: 1768064
[TBL] [Abstract][Full Text] [Related]
34. Induction of intracellular and plasma 2',5'-oligoadenylate synthetase by pentostatin.
Ho AD; Klotzbücher A; Gross A; Dietz G; Mestan J; Jakobsen H; Hunstein W
Leukemia; 1992 Mar; 6(3):209-14. PubMed ID: 1564958
[TBL] [Abstract][Full Text] [Related]
35. The interferon/2-5A synthetase system in primary preleukaemia patients.
Justesen J; Hokland P; Hokland M
Prog Clin Biol Res; 1985; 202():439-47. PubMed ID: 3868780
[No Abstract] [Full Text] [Related]
36. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
37. (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.
Schattner A; Merlin G; Bregman V; Hahn T; Levin S; Revel M; Wallach D
Clin Exp Immunol; 1984 Aug; 57(2):265-70. PubMed ID: 6467673
[TBL] [Abstract][Full Text] [Related]
38. Discordant effect of interferon on natural killer activity and tumor cell sensitivity to lysis in hairy cell leukemia.
Lahat N; Aghai E; Kotler A; Kinarty A; Sobel E; Gruener N; Froom P
Blood; 1988 Apr; 71(4):1141-3. PubMed ID: 3258536
[TBL] [Abstract][Full Text] [Related]
39. Increase in 2',5'-oligoadenylate synthetase caused by deoxycoformycin in hairy cell leukaemia.
Ganeshaguru K; de Mel WC; Sissolak G; Catovsky D; Dearden CE; Mehta AB; Hoffbrand AV
Br J Haematol; 1992 Feb; 80(2):194-8. PubMed ID: 1550776
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
Teichmann JV; Sieber G; Ludwig WD; Ruehl H
Cancer; 1989 May; 63(10):1990-3. PubMed ID: 2702571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
